On August 1, 2019, PhorMed entered into multiple contracts to acquire five of Professor Richard L. Chang’s patent inventions.
These contracts cover patent assignments for the use of his compound, RP-323, in the treatment of Acute Myeloid Leukemia, Hodgkin’s Lymphoma, Parkinson’s disease, Stroke, and a new patent for treating platelets. The company’s goals for these technologies are to develop first line treatments and create a new class of drug for neurological diseases.
